Progression in sensing cardiac troponin biomarker charge transductions on semiconducting nanomaterials

• The progression of cardiac troponin detection from past to future are presented.
• Electrical label-free biosensors for cardiac troponin are discussed.
• The discussion focused on field-effect transistor-and capacitor-based devices.
• Surface functionalization, sensitivity, and innovation of devices are highlighted.
• They presented high sensitivity and specificity of real-time AMI determination.

A real-time ability to interpret the interaction between targeted biomolecules and the surface of semiconductors (metal transducers) into readable electrical signals, without biomolecular modification involving fluorescence dyes, redox enzymes, and radioactive labels, created by label-free biosensors has been extensively researched. Field-effect transistor (FET)- and capacitor-based biosensors are among the diverse electrical charge biosensing architectures that have drawn much attention for having charge transduction; thus, enabling the early and rapid diagnosis of the appropriate cardiac biomarkers at lower concentrations. These semiconducting material-based transducers are very suitable to be integrated with portable electronic devices for future online collection, transmission, reception, analysis, and reporting. This overview elucidates and clarifies two major electrical label-free systems (FET- and capacitor-based biosensors) with cardiac troponin (cTn) biomarker-mediated charge transduction for acute myocardial infarction (AMI) diagnosis. Advances in these systems are highlighted by their progression in bridging the laboratory and industry; the foremost technologies have made the transition from benchtop to bedside and beyond.

Figure optionsDownload as PowerPoint slide